Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Horse (Equine) Antibodies:
Go to our pre-filtered search.
Human Monoclonal CCL13 Primary Antibody for CyTOF, ELISA (Capture) - ABIN4899862
Gounni Abdelilah, Wellemans, Agouli, Guenounou, Hamid, Beck, Lamkhioued: Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. in Clinical immunology (Orlando, Fla.) 2006
In plasma, but not CSF (show CSF2 Antibodies), the bivariate MCP4 (CCL13)/ MCP1(CCL2 (show CCL2 Antibodies)) ratio is ca. twofold elevated in PTSD patients compared with healthy controls.
CCL13 expression is significantly upregulated in human masticatory mucosa during wound healing
The reduction of circulating levels of MCP-4, eotaxin-3 (show CCL26 Antibodies), and MIP-1beta (show CCL4 Antibodies) could be one of the mechanisms by which bariatric surgery contributes to the reduction of cardiovascular risk in these patients.
CCL13 levels in serum and synovial fluid may serve as a biomarker for the progression of osteoarthritis.
identified 13 ADCC-activated genes. Six gene expression assays including 8 of the 13 genes (CCL3 (show CCL3 Antibodies), CCL4/CCL4L1 (show CCL4 Antibodies)/CCL4L2, CD160 (show CD160 Antibodies), IFNG (show IFNG Antibodies), NR4A3 (show NR4A3 Antibodies) and XCL1 (show XCL1 Antibodies)/XCL2 (show XCL2 Antibodies)) were analyzed in 127 kidney biopsies
CCL13 is an antimicrobial protein with bacteriocidal activity against E. coli.
Data suggest that CCL13 binds to several chemokine (show CCL1 Antibodies) receptors (CCR1, CCR2 (show CCR2 Antibodies), and CCR3 (show CCR3 Antibodies)), allowing CCL13 to elicit different effects on target cells of immune system. CCL13 is involved in pathology of chronic inflammatory/autoimmune diseases. [REVIEW]
MCP-4 and hsCRP may be the markers linking chronic inflammation in obesity and periodontal disease.
E(2) has adverse effects on the pathogenesis of RA as a result of unregulated cell death, increased TNF-alpha (show TNF Antibodies)-induced MMP-3 (show MMP3 Antibodies) production, and CCL13 overproduction, subsequently resulting in the disease progression of RA.
Data show that, for the small macrophages in COPD (show ARCN1 Antibodies), increased transcript and protein levels for CCL2 (show CCL2 Antibodies), CCL7 (show CCL7 Antibodies), CCL13 and CCL22 (show CCL22 Antibodies) with a more than 100-fold increase for CCL13 mRNA.
deletion of the gene encoding MMCP-4 (Mcpt4), markedly reduced late, but not early, infarct size by suppressing IGF-1 (show IGF1 Antibodies) degradation and, consequently, diminished cardiac dysfunction and adverse structural remodeling
Data indicate that a second-degree burn injury can initiate an immediate novel zonal degranulation of mast cell throughout all skin layers and a disruption of the epidermal tight junctions dependent on the nonredundant presence of mMCP4 and mMCP5 (show CMA1 Antibodies).
these results support the conclusion that mast cells can contribute to the initial lung injury induced by bleomycin through release of the MCPT4 chymase (show CMA1 Antibodies).
Mast cell chymase (show CMA1 Antibodies) degrades the alarmins heat shock protein 70 (show HSP70 Antibodies), biglycan (show BGN Antibodies), HMGB1 (show HMGB1 Antibodies), and interleukin-33 (IL-33 (show IL33 Antibodies)) and limits danger-induced inflammation.
Data from Mcp-4 (mast cell protease 4) knockout mice suggest Mcp-4 plays a pivotal role in the dynamic (in vivo and in vitro) conversion of systemic Big-endothelin-1 (show EDN1 Antibodies) to endothelin-1 (show EDN1 Antibodies) (1-31).
MCs (show SMCP Antibodies) exert protective functions after trauma, at least in part via mMCP-4, by suppressing exacerbated inflammation via their proteases.
The effects of interactions between mMCP-4 and TNF (show TNF Antibodies) in vivo by analyzing the features of a classic model of polymicrobial sepsis, were assessed.
mMCP-4 plays two different roles in the pathogenesis of experimental BP, by both activating MMP-9 (show MMP9 Antibodies) and by cleaving BP180 (show COL17A1 Antibodies), leading to injury of the hemidesmosomes and extracellular matrix of the basement membrane zone.
mMCP-4-deficient mice but not to mMCP-5 (show CMA1 Antibodies)-deficient mice revealing nonredundant actions for these two MC proteases in a model of innate inflammatory injury with remodeling.
MCP-4 contributes locally to the aggravation of glomerulonephritis by mediating a variety of proinflammatory effects.
This gene is one of several Cys-Cys (CC) cytokine genes clustered on the q-arm of chromosome 17. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for monocytes, lymphocytes, basophils and eosinophils, but not neutrophils. This chemokine plays a role in accumulation of leukocytes during inflammation. It may also be involved in the recruitment of monocytes into the arterial wall during artherosclerosis.
C-C motif chemokine 13
, monocyte chemoattractant protein 4
, monocyte chemotactic protein 4
, new CC chemokine 1
, small inducible cytokine subfamily A (Cys-Cys), member 13
, small-inducible cytokine A13
, monocyte chemotactic protein-4
, serosal mast cell protease